Advertisement

Topics

#news #biotech Sanofi and Regeneron to end antibody R&D pact by year’s end

08:55 EDT 3 Aug 2017 | Biotech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi and Regeneron to end antibody R&D pact by year’s end .Tucked away in the middle of its second-quarter results today, Regeneron announced that it and long-term Big … Continue reading

Cet article #news #biotech Sanofi and Regeneron to end antibody R&D pact by year’s end est apparu en premier sur Biotech 365.

Original Article: #news #biotech Sanofi and Regeneron to end antibody R&D pact by year’s end

NEXT ARTICLE

More From BioPortfolio on "#news #biotech Sanofi and Regeneron to end antibody R&D pact by year’s end"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...